The changes to clinical trial conduct necessitated by the COVID-19 outbreak is providing a “natural experiment” to test different techniques to run de-centralized clinical trials, representatives of the US Food & Drug Administration suggested during a 13-14 July meeting on the evolution of digital health systems in oncology.
“This pandemic in many ways functions as a natural experiment on home and community-based cancer innovation,” deputy commissioner for medical/scientific affairs Anand Shah observed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?